Zurcher Kantonalbank Zurich Cantonalbank Buys Shares of 9,538 Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,538 shares of the biotechnology company’s stock, valued at approximately $182,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Decheng Capital Management III Cayman LLC bought a new stake in Alpine Immune Sciences during the 3rd quarter valued at $76,810,000. Vanguard Group Inc. raised its holdings in Alpine Immune Sciences by 5.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company’s stock valued at $16,887,000 after acquiring an additional 70,912 shares during the period. Walleye Capital LLC raised its holdings in Alpine Immune Sciences by 13.1% during the 3rd quarter. Walleye Capital LLC now owns 186,273 shares of the biotechnology company’s stock valued at $2,133,000 after acquiring an additional 21,600 shares during the period. Nan Fung Group Holdings Ltd bought a new stake in Alpine Immune Sciences during the 3rd quarter valued at $2,087,000. Finally, Bank of New York Mellon Corp raised its holdings in Alpine Immune Sciences by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock valued at $1,062,000 after acquiring an additional 1,216 shares during the period. Institutional investors own 75.17% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Oppenheimer restated an “outperform” rating and set a $44.00 price target (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. HC Wainwright lowered shares of Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, April 11th. Wolfe Research restated a “peer perform” rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. SVB Leerink lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $42.00 to $65.00 in a research report on Friday, April 12th. Finally, Guggenheim assumed coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a “buy” rating and a $55.00 price target for the company. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Alpine Immune Sciences has a consensus rating of “Hold” and a consensus price target of $50.33.

Alpine Immune Sciences Stock Performance

Shares of ALPN opened at $64.64 on Wednesday. Alpine Immune Sciences, Inc. has a fifty-two week low of $7.25 and a fifty-two week high of $64.72. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of -101.00 and a beta of 0.97. The firm has a 50 day moving average price of $47.44 and a 200-day moving average price of $29.15.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The company had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million. As a group, equities research analysts predict that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current year.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.